<DOC>
	<DOC>NCT00184613</DOC>
	<brief_summary>This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.</brief_summary>
	<brief_title>Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects with type 2 diabetes for more than 2 years Subjects currently treated with unchanged insulin glargine dose (10 100 units) for 2 weeks Subjects currently treated with unchanged dose(s) for at least 1 month on one or two Oral Antidiabetic drugs BMI 25 40 kg/m2 HbA1c &lt; 9.5 % Known or suspected allergy to trial product(s) or related products Previous randomisation in this trial Pregnancy, breastfeeding, intention of becoming pregnant or premenopausal women judged not to be using adequate contraceptive measures (Only sterilisation, intra uterine devices and contraceptive pills are considered adequate contraceptive methods) Mental incapacity, unwillingness or language barriers precluding adequate understanding and cooperation. Any other significant illness such as endocrine, cardiac, neurological, malignant or other pancreatic illness judged by Investigator Participation in other studies within the last three months</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>